300+
Patients samples processed
94.4%
Sensitivity (vs OncoDiscover®)
9+
Cancer types tested
The OncoMetastat® device
OncoMetastat® Device
For research use only. Safety and effectiveness have not been established.
OncoMetastat® Digital Screen and pump
OncoMetastat® Components
Core Technology
Precision engineering
for CTC depletion.
OncoMetastat® is an investigational extracorporeal blood-processing platform, inspired by blood-dialysis principles, and envisaged to selectively capture and deplete circulating tumor cells (CTCs) from a patient’s blood while maintaining blood integrity. Designed with a focus on precision and safety, the prototype is currently under evaluation for its potential research relevance to metastasis and broader cancer management.
Spiral Filtration System
Spiral channel housing CTC-capturing glass beads 3D printed with biomedical grade resin can filter 1-10 ml clinical blood sample.
Affinity Based System
Ligand-conjugated glass beads designed to capture circulating tumor cells (CTCs) for investigational evaluation. Ligands are EpCAM, Transferrin and N-Cadherin.
Biocompatible Design
Constructed from non-immunogenic materials to support durability and biocompatibility testing.
Built-in Safety Controls
Includes provisions for anti-coagulant handling and mixing systems during prototype testing.
Continuous Automated Operation
Designed to model gentle, continuous and automated blood circulation similar to dialysis principles for investigational use.
Algorithmic Image Analysis
Use of image processing algorithms for automated cell quantification and counting.
Process
How OncoMetastat® works.
A closed-loop, extracorporeal process designed for gentle, continuous CTC depletion.
Blood Collection
A clinical blood sample (1–10 ml) is collected via a standard BCT (Blood Collection Tube) and loaded into the cartridge through the aspirator needle system.
Spiral Channel Processing
The peristaltic pump circulates blood through the 3D-printed spiral channel plate. The stage vibrator ensures continuous, uniform flow and prevents bead aggregation.
Affinity-Based CTC Capture
EpCAM, Transferrin, and N-Cadherin conjugated glass beads selectively bind circulating tumor cells as blood passes through the bead matrix.
Effluent Return & Analysis
Processed blood exits via the effluent line. Captured CTCs on the glass bead substrate are then stained and quantified using CK18/DAPI fluorescence imaging.
Clinical Performance
Data-backed research results.
Analytical Concordance Between OncoMetastat® and OncoDiscover® (N = 32)
17
True Positives
01
False Positives
01
False Negatives
13
True Negatives
94.4 %
Sensitivity
92.9 %
Specificity
94.4 %
PPV (Positive Predictive Value)
92.9 %
NPV (Negative Predictive Value)
93.8 %
Accuracy
93.7 %
Balanced Accuracy
OncoDiscover® is a DCGI-approved CTC enumeration assay employing EpCAM immunocapture and CK/CD45/DAPI staining; it served as the internal reference method in this preliminary analytical assessment. Data are from internal studies and has not been reviewed or approved by the U.S. FDA.
CTC Captured by
OncoMetastat®
Brightfield
DAPI
CK18
Merge
CTCs Captured on OncoMetastat® Platform on the EpCAM/Tf functionalized glass bead.
Blood Parameter Testing with OncoMetastat®
Evaluation of Potential Hemolysis in OncoMetastat® (OMS)
0.9 %
OncoSpiral
0.8 %
Glass Beads
<2.0 %
OMS Device
Blood Protein Level Changes During OncoMetastat® Processing
70
mg/m
Control Serum
68.96
mg/m
Processed Serum
1.5 %
Protein Loss to Processing
Evaluation of Leucocyte (WBC) Adsorption on OncoMetastat® Beads
2+/-1
WBC Count (Bead-adherent WBCs)
OMS Processing
1+/-1
WBC Count (Bead-adherent WBCs)
OMS (with Vibration)
Evaluation of OncoMetastat® Induced Pyrogenicity
37 °C
Body Temperature
Control
37+/-0.5 °C
Body Temperature
OMS
References
-
Khandare, et. al. Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient’s whole blood. ASCO 2026
-
Khandare, et. al. Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates. AACR 2026
-
Khandare, et. al. Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. J Clin Oncol 2025; 43.
-
Khandare, et. al. Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate. The Journal of Liquid Biopsy 2025; 9; 100334.
-
Khandare, et. al. Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. J Clin Oncol 2022; 40.
-
Khandare, et. al. Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients. J Clin Oncol 2020; 38.
The OncoMetastat® technology aims to pioneer an innovative, research-driven strategy as a new therapeutic direction in preventing and delaying cancer metastasis.
Our
Publications
In collaboration with researchers and thought leaders around the world, OncoMetastat® combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc
